The stock of Cidara Therapeutics Inc (CDTX) has gone down by -3.90% for the week, with a -15.47% drop in the past month and a -12.22% drop in the past quarter. The volatility ratio for the week is 7.59%, and the volatility levels for the past 30 days are 7.94% for CDTX. The simple moving average for the past 20 days is -7.60% for CDTX’s stock, with a -35.19% simple moving average for the past 200 days.

Is It Worth Investing in Cidara Therapeutics Inc (NASDAQ: CDTX) Right Now?

Moreover, the 36-month beta value for CDTX is 1.19.

The average price recommended by analysts for Cidara Therapeutics Inc (CDTX) is $4.50, which is $3.76 above the current market price. The public float for CDTX is 82.05M and currently, short sellers hold a 1.51% of that float. On November 17, 2023, CDTX’s average trading volume was 446.41K shares.

CDTX) stock’s latest price update

The stock of Cidara Therapeutics Inc (NASDAQ: CDTX) has decreased by -7.83 when compared to last closing price of 0.80.Despite this, the company has seen a loss of -3.90% in its stock price over the last five trading days. Seeking Alpha reported 2023-09-22 that Janssen’s decision to proceed with CD388 further de-risks Cidara Therapeutics (CDTX) and validates the potential of the Cloudbreak platform. Combined with impressive preclinical data by oncology candidates presented in the Virtual Research & Development Day I upgrade my recommendation to “Strong buy”. CDTX’s cash runway is limited, but they are eligible for additional non-dilutive capital and I expect more partnerships will be formed to support Cloudbreak development.

Analysts’ Opinion of CDTX

Many brokerage firms have already submitted their reports for CDTX stocks, with H.C. Wainwright repeating the rating for CDTX by listing it as a “Buy.” The predicted price for CDTX in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 03, 2021 of the previous year 2021.

CDTX Trading at -18.33% from the 50-Day Moving Average

After a stumble in the market that brought CDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.76% of loss for the given period.

Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares sank -16.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.97% lower at present.

During the last 5 trading sessions, CDTX fell by -7.08%, which changed the moving average for the period of 200-days by -47.39% in comparison to the 20-day moving average, which settled at $0.7938. In addition, Cidara Therapeutics Inc saw -2.16% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CDTX starting from Sandison Taylor, who sale 18,793 shares at the price of $0.95 back on Sep 11. After this action, Sandison Taylor now owns 363,757 shares of Cidara Therapeutics Inc, valued at $17,810 using the latest closing price.

Tari Leslie, the CHIEF SCIENTIFIC OFFICER of Cidara Therapeutics Inc, sale 18,469 shares at $0.95 during a trade that took place back on Sep 11, which means that Tari Leslie is holding 275,710 shares at $17,509 based on the most recent closing price.

Stock Fundamentals for CDTX

Current profitability levels for the company are sitting at:

The net margin for Cidara Therapeutics Inc stands at -46.35. The total capital return value is set at -237.30, while invested capital returns managed to touch -298.12. Equity return is now at value -366.84, with -48.15 for asset returns.

When we switch over and look at the enterprise to sales, we see a ratio of 0.68, with the company’s debt to enterprise value settled at 0.06. The receivables turnover for the company is 11.49 and the total asset turnover is 1.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.50.


To wrap up, the performance of Cidara Therapeutics Inc (CDTX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.